These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. The function and dysfunction of memory CD8 Reading JL; Gálvez-Cancino F; Swanton C; Lladser A; Peggs KS; Quezada SA Immunol Rev; 2018 May; 283(1):194-212. PubMed ID: 29664561 [TBL] [Abstract][Full Text] [Related]
26. Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer. Zhang F; Bai H; Gao R; Fei K; Duan J; Zhang Z; Wang J; Hu X Cancer Immunol Immunother; 2020 Dec; 69(12):2599-2611. PubMed ID: 32591861 [TBL] [Abstract][Full Text] [Related]
27. Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. Chow MT; Ozga AJ; Servis RL; Frederick DT; Lo JA; Fisher DE; Freeman GJ; Boland GM; Luster AD Immunity; 2019 Jun; 50(6):1498-1512.e5. PubMed ID: 31097342 [TBL] [Abstract][Full Text] [Related]
28. Early CD8 T-cell memory precursors and terminal effectors exhibit equipotent in vivo degranulation. Yuzefpolskiy Y; Baumann FM; Kalia V; Sarkar S Cell Mol Immunol; 2015 Jul; 12(4):400-8. PubMed ID: 25066419 [TBL] [Abstract][Full Text] [Related]
29. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Kim CG; Kim KH; Pyo KH; Xin CF; Hong MH; Ahn BC; Kim Y; Choi SJ; Yoon HI; Lee JG; Lee CY; Park SY; Park SH; Cho BC; Shim HS; Shin EC; Kim HR Ann Oncol; 2019 Jul; 30(7):1104-1113. PubMed ID: 30977778 [TBL] [Abstract][Full Text] [Related]
30. The Emerging Role of CD8 Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F Front Immunol; 2018; 9():1904. PubMed ID: 30158938 [TBL] [Abstract][Full Text] [Related]
31. Type 1 conventional dendritic cells maintain and guide the differentiation of precursors of exhausted T cells in distinct cellular niches. Dähling S; Mansilla AM; Knöpper K; Grafen A; Utzschneider DT; Ugur M; Whitney PG; Bachem A; Arampatzi P; Imdahl F; Kaisho T; Zehn D; Klauschen F; Garbi N; Kallies A; Saliba AE; Gasteiger G; Bedoui S; Kastenmüller W Immunity; 2022 Apr; 55(4):656-670.e8. PubMed ID: 35366396 [TBL] [Abstract][Full Text] [Related]
32. A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. D'Amico L; Menzel U; Prummer M; Müller P; Buchi M; Kashyap A; Haessler U; Yermanos A; Gébleux R; Briendl M; Hell T; Wolter FI; Beerli RR; Truxova I; Radek Š; Vlajnic T; Grawunder U; Reddy S; Zippelius A J Immunother Cancer; 2019 Jan; 7(1):16. PubMed ID: 30665463 [TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Hargadon KM; Johnson CE; Williams CJ Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692 [TBL] [Abstract][Full Text] [Related]
34. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Blackburn SD; Shin H; Freeman GJ; Wherry EJ Proc Natl Acad Sci U S A; 2008 Sep; 105(39):15016-21. PubMed ID: 18809920 [TBL] [Abstract][Full Text] [Related]
35. [The "immune checkpoints", how does it work]. Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999 [TBL] [Abstract][Full Text] [Related]
36. Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer. Manjarrez-Orduño N; Menard LC; Kansal S; Fischer P; Kakrecha B; Jiang C; Cunningham M; Greenawalt D; Patel V; Yang M; Golhar R; Carman JA; Lezhnin S; Dai H; Kayne PS; Suchard SJ; Bernstein SH; Nadler SG Front Immunol; 2018; 9():1613. PubMed ID: 30123214 [TBL] [Abstract][Full Text] [Related]
37. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777 [TBL] [Abstract][Full Text] [Related]
39. Recent advances in the clinical development of immune checkpoint blockade therapy. Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647 [TBL] [Abstract][Full Text] [Related]
40. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells. Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]